This article first appeared on GuruFocus .
Release Date: July 28, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Indoco Remedies Ltd ( BOM:532612 ) reported a year-on-year standalone operational revenue growth of 5.8% to $4081 million, with consolidated revenue increasing by 8.2% to $4662 million.
-
The company achieved a standalone EBITDA margin of 10.3%, reflecting strong operational momentum.
-
Successful regulatory audits were completed, including EU GMP certification for Baddi Unit 3 and a zero-observation pre-approval inspection by the US FDA at the Indoco Stability Center.
-
The domestic formulations business recorded revenues of $2040 million, maintaining a solid position in the Indian pharma market.
-
International formulations contributed 35% of Q1 FY27 revenue, with the US business growing by 62.2% year-on-year.
Negative Points
-
The company faced a decline in gross margins due to increased costs of goods, impacted by supply chain issues and material shortages.
-
Emerging markets experienced a revenue decline, attributed to temporary market conditions and product availability challenges.
-
The European market showed flat growth, with timing issues affecting product releases.
-
Debt levels remain high, with a total debt of around 930 crore, impacting financial flexibility.
-
The US business, particularly the sterile segment, is not yet profitable due to ongoing regulatory challenges and remediation costs.
Q & A Highlights
-
Warning! GuruFocus has detected 5 Warning Signs with BOM:532612.
-
Is BOM:532612 fairly valued? Test your thesis with our free DCF calculator.
Q: Any update from the US FDA about the plant? A: No, we've not heard anything yet, but let's keep our fingers crossed, hoping in the next couple of months. (Respondent: Unidentified_4)
Q: On our international business, revenues are largely flat. The US business has grown, but there's a degrowth in the emerging markets. Are there any concerns or do you expect these markets to grow this year? A: The emerging business is a branded formulations market, and sometimes for the March quarter end, there is a bit of a push. This is only a temporary one-quarter glitch. (Respondent: Unidentified_4)
Q: On the domestic business, Indoco standalone business plus the war, even that business has been flat. Any comments on that? A: The TOP10 large brands of the company have almost all segments in double-digit positive growth except two products, anti-infective and respiratory, which are very seasonal. (Respondent: Unidentified_4)
Q: What would be the potential for these brands in the India business? Can we grow double-digits here for the next one to two years? A: As the TOP10 brands contribute more to total turnover, we are more in control of delivering a consistent performance. Expect higher single-digit to double-digit growth in India business going forward. (Respondent: Unidentified_4)
Q: On the margins, while the margins have grown, gross margins have taken a hit for the quarter. Do you expect these gross margins to improve? A: This quarter, we had an impact of the increase in cost of goods due to the water situation and shortages of materials. Our cost of goods has gone up by two percentage points. (Respondent: Unidentified_4)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
